Your browser doesn't support javascript.
loading
Haploinsufficiency of phosphodiesterase 10A activates PI3K/AKT signaling independent of PTEN to induce an aggressive glioma phenotype.
Nuechterlein, Nicholas; Shelbourn, Allison; Szulzewsky, Frank; Arora, Sonali; Casad, Michelle; Pattwell, Siobhan; Merino-Galan, Leyre; Sulman, Erik; Arowa, Sumaita; Alvinez, Neriah; Jung, Miyeon; Brown, Desmond; Tang, Kayen; Jackson, Sadhana; Stoica, Stefan; Chittaboina, Prashant; Banasavadi-Siddegowda, Yeshavanth K; Wirsching, Hans-Georg; Stella, Nephi; Shapiro, Linda; Paddison, Patrick; Patel, Anoop P; Gilbert, Mark R; Abdullaev, Zied; Aldape, Kenneth; Pratt, Drew; Holland, Eric C; Cimino, Patrick J.
Affiliation
  • Nuechterlein N; Neuropathology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
  • Shelbourn A; Neuropathology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
  • Szulzewsky F; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington 98109, USA.
  • Arora S; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington 98109, USA.
  • Casad M; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington 98195, USA.
  • Pattwell S; Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, Washington 98145, USA.
  • Merino-Galan L; Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, Washington 98145, USA.
  • Sulman E; Department of Radiation Oncology, New York University Grossman School of Medicine, New York, New York 11220, USA.
  • Arowa S; Neuropathology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
  • Alvinez N; Neuropathology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
  • Jung M; Neurosurgical Oncology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
  • Brown D; Neurosurgical Oncology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
  • Tang K; Developmental Therapeutics and Pharmacology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
  • Jackson S; Developmental Therapeutics and Pharmacology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
  • Stoica S; Neurosurgery Unit for Pituitary and Inheritable Diseases, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
  • Chittaboina P; Neurosurgery Unit for Pituitary and Inheritable Diseases, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
  • Banasavadi-Siddegowda YK; Molecular and Therapeutics Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
  • Wirsching HG; Department of Neurology, University Hospital, University of Zurich, Zurich 8091, Switzerland.
  • Stella N; Department of Pharmacology, University of Washington, Seattle, Washington 98195, USA.
  • Shapiro L; Paul G. Allen School of Computer Science and Engineering, University of Washington, Seattle, Washington 98195, USA.
  • Paddison P; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington 98109, USA.
  • Patel AP; Department of Neurosurgery, Preston Robert Tisch Brain Tumor Center, Duke University, Durham, North Carolina 27710, USA.
  • Gilbert MR; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20814, USA.
  • Abdullaev Z; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20814, USA.
  • Aldape K; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20814, USA.
  • Pratt D; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20814, USA.
  • Holland EC; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington 98109, USA.
  • Cimino PJ; Neuropathology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA; pj.cimino@nih.gov.
Genes Dev ; 38(5-6): 273-288, 2024 04 17.
Article in En | MEDLINE | ID: mdl-38589034
ABSTRACT
Glioblastoma is universally fatal and characterized by frequent chromosomal copy number alterations harboring oncogenes and tumor suppressors. In this study, we analyzed exome-wide human glioblastoma copy number data and found that cytoband 6q27 is an independent poor prognostic marker in multiple data sets. We then combined CRISPR-Cas9 data, human spatial transcriptomic data, and human and mouse RNA sequencing data to nominate PDE10A as a potential haploinsufficient tumor suppressor in the 6q27 region. Mouse glioblastoma modeling using the RCAS/tv-a system confirmed that Pde10a suppression induced an aggressive glioma phenotype in vivo and resistance to temozolomide and radiation therapy in vitro. Cell culture analysis showed that decreased Pde10a expression led to increased PI3K/AKT signaling in a Pten-independent manner, a response blocked by selective PI3K inhibitors. Single-nucleus RNA sequencing from our mouse gliomas in vivo, in combination with cell culture validation, further showed that Pde10a suppression was associated with a proneural-to-mesenchymal transition that exhibited increased cell adhesion and decreased cell migration. Our results indicate that glioblastoma patients harboring PDE10A loss have worse outcomes and potentially increased sensitivity to PI3K inhibition.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Glioblastoma / Glioma Limits: Animals / Humans Language: En Journal: Genes Dev Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Glioblastoma / Glioma Limits: Animals / Humans Language: En Journal: Genes Dev Year: 2024 Document type: Article